Logo image of ICU

SEASTAR MEDICAL HOLDING CORP (ICU) Stock Fundamental Analysis

NASDAQ:ICU - Nasdaq - US81256L2034 - Common Stock - Currency: USD

1.25  0 (0%)

Fundamental Rating

1

Overall ICU gets a fundamental rating of 1 out of 10. We evaluated ICU against 191 industry peers in the Health Care Equipment & Supplies industry. ICU has a bad profitability rating. Also its financial health evaluation is rather negative. ICU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ICU has reported negative net income.
ICU had a negative operating cash flow in the past year.
ICU had negative earnings in each of the past 5 years.
In the past 5 years ICU always reported negative operating cash flow.
ICU Yearly Net Income VS EBIT VS OCF VS FCFICU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

ICU has a Return On Assets of -533.06%. This is amonst the worse of the industry: ICU underperforms 95.81% of its industry peers.
Industry RankSector Rank
ROA -533.06%
ROE N/A
ROIC N/A
ROA(3y)-587.39%
ROA(5y)-528.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICU Yearly ROA, ROE, ROICICU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

ICU has a better Gross Margin (100.00%) than 100.00% of its industry peers.
The Profit Margin and Operating Margin are not available for ICU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ICU Yearly Profit, Operating, Gross MarginsICU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

ICU has more shares outstanding than it did 1 year ago.
ICU has a better debt/assets ratio than last year.
ICU Yearly Shares OutstandingICU Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ICU Yearly Total Debt VS Total AssetsICU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -54.39, we must say that ICU is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ICU (-54.39) is worse than 92.15% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -54.39
ROIC/WACCN/A
WACCN/A
ICU Yearly LT Debt VS Equity VS FCFICU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

2.3 Liquidity

A Current Ratio of 0.55 indicates that ICU may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.55, ICU is doing worse than 92.67% of the companies in the same industry.
A Quick Ratio of 0.55 indicates that ICU may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.55, ICU is doing worse than 90.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.55
ICU Yearly Current Assets VS Current LiabilitesICU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.48% over the past year.
EPS 1Y (TTM)52.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ICU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.61% yearly.
Based on estimates for the next years, ICU will show a very strong growth in Revenue. The Revenue will grow by 202.89% on average per year.
EPS Next Y80.14%
EPS Next 2Y36.61%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year358.72%
Revenue Next 2Y202.89%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

ICU Yearly Revenue VS EstimatesICU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 500K 1M 1.5M 2M
ICU Yearly EPS VS EstimatesICU Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ICU. In the last year negative earnings were reported.
Also next year ICU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICU Price Earnings VS Forward Price EarningsICU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICU Per share dataICU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

ICU's earnings are expected to grow with 36.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.61%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ICU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEASTAR MEDICAL HOLDING CORP

NASDAQ:ICU (4/23/2025, 4:30:02 PM)

1.25

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-12 2025-05-12
Inst Owners2.52%
Inst Owner Change2.45%
Ins Owners1.11%
Ins Owner Change0.04%
Market Cap10.90M
Analysts80
Price Target7.14 (471.2%)
Short Float %4.21%
Short Ratio0.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.75%
Min EPS beat(2)-0.12%
Max EPS beat(2)3.62%
EPS beat(4)2
Avg EPS beat(4)1.44%
Min EPS beat(4)-25.41%
Max EPS beat(4)27.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33%
Min Revenue beat(2)-55.78%
Max Revenue beat(2)-10.23%
Revenue beat(4)0
Avg Revenue beat(4)-66.5%
Min Revenue beat(4)-100%
Max Revenue beat(4)-10.23%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)16.13%
EPS NQ rev (3m)16.13%
EPS NY rev (1m)28.84%
EPS NY rev (3m)28.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 80.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.78
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0.02
BVpS-0.25
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -533.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-587.39%
ROA(5y)-528.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.55
Altman-Z -54.39
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.64%
EPS Next Y80.14%
EPS Next 2Y36.61%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year358.72%
Revenue Next 2Y202.89%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.63%
OCF growth 3YN/A
OCF growth 5YN/A